JO
BIAF icon

John Overdeck’s bioAffinity Technologies BIAF Stock Holding History

John Overdeck’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-48
Closed -$31.8K – 3040
2023
Q4 		$31.8K Hold
48
– – ﹤0.01% 3033
2023
Q3 		$25.2K Sell
48
-1
-2% -$762 ﹤0.01% 2862
2023
Q2 		$40K Sell
49
-10
-17% -$8.28K ﹤0.01% 2848
2023
Q1 		$50.2K Buy
+59
New +$51.2K ﹤0.01% 2753

Other funds holding BIAF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

John Overdeck's BIAF Position: Q1 2024 in Review

John Overdeck sold out of bioAffinity Technologies (BIAF) in Q1 2024, closing a stake of 48 shares — an estimated $31.8K sold.

John Overdeck first reported a position in BIAF in Q1 2023 and held it in 4 quarters. The position peaked at $50.2K in Q1 2023. 10 funds tracked by Wall St. Rank hold BIAF as of Q1 2024.

  • John Overdeck reported no remaining bioAffinity Technologies position as of Q1 2024 after selling out during the quarter.
  • John Overdeck sold 48 bioAffinity Technologies shares in Q1 2024, an estimated $31.8K.
  • John Overdeck first reported a position in bioAffinity Technologies in Q1 2023 and held it in 4 quarters.
  • John Overdeck's bioAffinity Technologies position peaked at $50.2K in Q1 2023.
  • 10 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q1 2024.

Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.